TNFSF10 and neoplasm: Importantly, the inhibition of tumor growth in the aloperine + TRAIL or aloperine + bortezomib groups was significantly superior to that of aloperine alone (P < 0.05), indicating that aloperine augments the growth inhibition of MM cells treated with TRAIL or bortezomib in vivo.